Interview with Bingshen Li, CEO, SinoGenoMax
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
Address: No. 3-707 North Yongchang Road,BDA,Beijing 100176,P.R.China.,China
Tel: +86 10 6788 3332
Web: http://www.sinogenomax.com/en
As one of the largest genomics-based biotech companies in China, SinoGenoMax Co.,Ltd. was incorporated in September 1998 by a joint investment from the Beijing Municipal Science & Technology Commission and Beijing Boda Sci-Tech Venture Capital Ltd. Its founding members include the Chinese Academy of Medical Sciences, Peking University, the Chinese Academy of Science, and the Beijing Institute of Medical Sciences. The affililated institute, Chinese National Human Genome Center of Beijing (CHGB) was established in October 1998 at SinoGenoMax.
SinoGenoMax participated in the International Human Genome Sequencing Project, and has been closely involved in several major genome-related research projects such as pathogenic microorganism sequencing projects, Chinese population single nucleotide polymorphism (SNP) genotyping project, and other disease genome research projects.
Originally focused on DNA sequencing and analysis, SinoGenoMax has subsequently expanded its expertise in all aspects of molecular biology and protein biology. SinoGenoMax has built up several independent technical groups including genomics group, proteomics group, and molecular biology group. In particular, SinoGenoMax has perfected a rigorous quality-management system to implement process monitoring and quality control for all the procedures we perform. SinoGenoMax has passed the ISO 9001:2000 international certification of quality management system since 2004, and is now preparing to obtain ISO/IEC 17025:2005 accreditation of testing laboratory.
There are currently 100 employees working at SinoGenoMax located in Beijing Economic-Technological Development Area. SinoGenoMax’s 5,000 square meter laboratory building is fully equipped with top class facilities including DNA Sequencers, mass spectrometry, HPLC, Microarray Chip Reader, and lab automation workstation, for high throughput operation and analysis in genomics and proteomics research. A proprietary Laboratory Information Management System(LIMS) has been implemented for standardized management of samples,data and work flow, and all procedures are performed under the guidance of corresponding SOPs.
In the past few years, SinoGenoMax has successfully provided high quality and cost-effective services for several international pharmaceutical companies. Whether in the scientific research or industrial of production, the widely recognized achievements have enabled SinoGenoMax to become the best biotechnology service company at home and abroad.
Large-scale DNA sequencing, Bioinformatics, Protein expression & Purification, Protein Seperation & Identification, Antibody Production, Functional Genomics & Drug Disc. Platform, Genome-Based Target Validation, Pathway-Based Target Validation, siRNA-Based Drug Screening
SinoGenoMax was founded in 1998 with the purpose of participating in the Human Genome Project. Could you give us an overview of the company’s activities since then and the transformation…
George Zhang, founder and chairman of Shenzhen-based ultrasound equipment developer and manufacturer, PRO, introduces his company’s groundbreaking high intensity focused ultrasound (HIFU) Noninvasive Therapy technology, and developing an innovative mindset…
As Professor of Neuroscience and Pain Medicine and director of the center for pain medicine at Southern University of Science and Technology (SUSTech) since 2016, Dr. Xue-jun Song explains the…
Shine Liu Xiancheng, CEO and founder of Lifotronic, discusses the rise of the medtech manufacturer over its ten years of existence, its commitment to R&D, and improving China’s innovation capacity.…
Zhang Guojian and Zhang Erying of in-vitro diagnostics manufacturer KingFocus Biomedical, introduce their company’s innovative ‘quantum dots’ technology, its development, client list, and the benefits of being based in Shenzhen.…
Dr. Grace Zhou, dean of SIIBR, discusses the Institute’s priorities, the benefits of being located in Shenzhen and the city’s potential as a global innovation hub. Zhou also outlines the…
Dr. Tang Dajie, founder and CEO of investment vehicle Triwise Capital, discusses the numerous investment opportunities in Shenzhen’s life sciences sector and the city’s unique geographical and economic positioning. Dr.…
Tian Yaolin, CEO of Shenzhen Govita Medical Laboratory, shares the exciting story of Govita’s start-up in the past two years; their robust and innovative business model centered on healthcare management…
Signed in June 2010, the Economic Cooperation Framework Agreement (ECFA) between Taiwan and China was set to reduce tariffs and commercial barriers between the two countries. Obviously, such a deal…
Many of your counterparts have spoken about the unique operational and strategic challenges China poses to their organizations. How does PAREXEL adapt itself to compete in China, and how does…
Every “sea turtle” has a different story. What’s yours, and how did you come to found Wincon? I am a “sea turtle” just like other Chinese returnees. I’m a medical doctor…
You are the CEO of GCP CMIC ClinPlus in addition to R&G PharmaStudies, and before that you headed a number of companies as well. Could you introduce yourself and all…
We’re meeting you just after a conference where you were a keynote speaker. Could you share with us some of your insights from the day’s events? The conference was a…
See our Cookie Privacy Policy Here
